Helix BioPharma (TSX:HBP) shared the publication of a peer-reviewed V-DOS47 manuscript in “Frontiers in Immunology” journal.
As quoted in the press release:
V-DOS47 is Helix’s second DOS47 development candidate following L-DOS47, which is currently in clinical testing for the treatment of non-small cell lung cancer.
The article, entitled “Development and Characterization of a Camelid Single Domain Antibody-Urease Conjugate That Targets Vascular Endothelial Growth Factor Receptor 2”, describes the design and construction of V-DOS47 for breast cancer and other potential indications. The paper can be accessed online at https://doi.org/10.3389/fimmu.2017.00956.
“We are very pleased to present our V-DOS47 research work through a peer-reviewed forum,” said Heman Chao, Ph.D., Chief Executive & Scientific Officer of Helix. “V-DOS47 research and development activities, coordinated by our Polish subsidiary, Helix Immuno-Oncology S.A., have been progressing well. We continue to work closely with our team in Poland to advance the DOS47 platform.”